Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.80 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Binodenoson SCHEMBL8922719 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL12877884 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL10089218 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL724955 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL724956 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL23898649 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL940135 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL8932230 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL29379829 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL13259764 | 0.90 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | The united States of America,as represented by Secretary,Dept.,of Health and Human Services (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | NT5E, NT5C2, NT5C3B | ADORA2A 4/4885ADORA1 9/4885ADORA2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.